Novartis | NOVN - Gross Profit On Sales

Stock Price
115.62
Daily Change
2.08 1.83%
Monthly
-3.49%
Yearly
25.92%
Q2 Forecast
113.62

Novartis reported $10.07B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alcon AG USD 1.52B 58M Dec/2025
Almirall EUR 429.87M 180.02M Dec/2025
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Autolus Therapeutics Ltd USD -1.04M 6.41M Dec/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Fresenius EUR 1.51B 214M Dec/2025
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 977M 13M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
J&J USD 17.24B 642M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 2.96B 252M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Orion EUR 254M 254.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Philips EUR 2.29B 377M Dec/2025
Recordati EUR 432.41M 8.56M Sep/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025